Application of a Precision‐Dosing Model to a Real‐World Cohort of Patients on Infliximab Maintenance Therapy: Drug Usage and Cost Analysis
The Journal of Clinical Pharmacology · 2024
DOI: 10.1002/jcph.2384 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Pharmacology, 2024. Verfasst von Anke L Nguyen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Central Clinical School, Monash University and Alfred Health, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Crohn Disease, Colitis, Ulcerative, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Precision‐dosing models forecast infliximab doses to achieve targeted trough concentrations in patients with inflammatory bowel disease (IBD). These models have shown to reduce nonresponse and improve patient outcomes. We compared infliximab doses determined by iDOSE precision dosing with standard dosing, and the associated drug costs, in patients with IBD. In this retrospective study, patients with IBD treated with infliximab every 8 weeks at 5 mg/kg were included. An infliximab dose was named dose X if 3 previous infliximab doses, laboratory values including trough infliximab concentrations, and the patient's weight were recorded. The actual dose X was compared to an iDOSE‐predicted dose X. Net drug use and costs were evaluated. A total of 174 patients—56% men; median age, 36 (interquartile range, 29‐47) years; 135 with Crohn disease; and 31 with ulcerative colitis—were included, with 417 dose X recordings. Median prior infliximab therapy was 2 (0‐4) years. Comparing actual dose X with predicted dose X, 52% and 32% of doses were subtherapeutic when aiming for trough concentrations of 5‐10 and 3‐7 μg/mL, respectively. Treatment costs increased by 102% and 29% for the 2 trough ranges, respectively. On multivariate regression analysis, subtherapeutic infliximab concentrations were associated with ulcerative colitis compared with Crohn disease (odds ratio, 9.81; 95% confidence interval, 1.28‐75.40; P = .028) and predose X infliximab trough concentration [odds ratio, 0.07; 95% confidence interval, 0.03‐0.15; P < .001]. Over half of maintenance infliximab drug doses were too low to achieve infliximab blood concentrations of 5 μg/mL or greater. While applying precision dosing may improve patient outcomes, drug costs could be considerably greater.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Central Clinical School, Monash University and Alfred Health, Melbourne, Victoria, Australia.
- Department of Gastroenterology, Monash Health, Melbourne, Australia.
- Projections Research, Inc., Phoenixville, PA, USA.
- University of South Australia, Adelaide, Australia.
ORCID-Profile: Anke L Nguyen, Diane R Mould
Zitieren
APA
Nguyen, A. L., Gibson, P. R., Upton, R. N., Mould, D. R., & Sparrow, M. P. (2024). Application of a Precision‐Dosing Model to a Real‐World Cohort of Patients on Infliximab Maintenance Therapy: Drug Usage and Cost Analysis. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.2384
Vancouver
Nguyen AL, Gibson PR, Upton RN, Mould DR, Sparrow MP. Application of a Precision‐Dosing Model to a Real‐World Cohort of Patients on Infliximab Maintenance Therapy: Drug Usage and Cost Analysis. The Journal of Clinical Pharmacology. 2024. doi:10.1002/jcph.2384
BibTeX
@article{Nguyen2024,
author = {Nguyen, Anke L and Gibson, Peter R and Upton, Richard N and Mould, Diane R and Sparrow, Miles P},
title = {Application of a Precision‐Dosing Model to a Real‐World Cohort of Patients on Infliximab Maintenance Therapy: Drug Usage and Cost Analysis},
journal = {The Journal of Clinical Pharmacology},
year = {2024},
doi = {10.1002/jcph.2384}
}
EUVIMED